Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

Xiang Zhou; Rongjian Xu; Tong Lu; Ran Xu; Chenghao Wang; Bo Peng; Xiaoyan Chang; Zhiping Shen; Kaiyu Wang; Jiaxin Shi; Jiaying Zhao; Lin-You Zhang

doi:doi:10.18632/aging.204957

← Back

Research Paper Volume 15, Issue 16 pp 8090—8112

Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma

Figure 3. Mutational landscape of HRD and non-HRD patients. (A) Top 20 mutation landscape of HRD patients in the TCGA-LUAD cohort. (B) Top 20 mutation landscape of non-HRD patients in the TCGA-LUAD cohort. The genes in red boxes are actionable genes. (C) Overlapping information of HRD and non-HRD mutated genes; actionable genes are only in non-HRD.